Research programme: interleukin-1 receptor associated kinase 4 inhibitors - Nimbus

Drug Profile

Research programme: interleukin-1 receptor associated kinase 4 inhibitors - Nimbus

Alternative Names: IRAK4 inhibitors - Nimbus Therapeutics; ND-2110; ND-2158; ND-346

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Nimbus Discovery
  • Developer Nimbus Therapeutics
  • Class Small molecules
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diffuse large B cell lymphoma; Haematological malignancies; Rheumatic disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatic-disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top